Neurogene completes dosing of 25 patients in NGN-401 Rett syndrome trial.

Neurogene Inc. successfully completed enrollment in its Embolden registrational trial for NGN-401, dosing 25 participants (exceeding the 20-patient target) with no safety concerns reported. Topline data is expected in the second half of 2027, potentially supporting a planned Biologics License Application submission for this investigational gene therapy.